UNSPSC 51151651: Methixene or metixene

This classification denotes an antiparkinsonian agent with the molecular formula C20H23NS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32VY6L26ZW, chemically known as 1-pipecoline, 3-(thioxanthen-9-yl)methyl-, hydrochloride but generally known as methixene, which bears US NIH Compound Identifier 4167. European Medicines Agency schedules Metixene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08897MIG. The term METHIXENE is an International Non-Proprietary Name.

World Health Organization schedules methixene in its Anatomical Therapeutic Chemical (ATC) Classification. Methixene or metixene bears US NLM identifiers UMLS ID C0066139 and NCI Concept Code C74162. SMILES: CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24.

UNSPSC 51151651 Methixene or metixene is a Commodity code that shows minimal recent state and local activity, with posted opportunities bearing little connection to the code's pharmaceutical scope. The single concrete state procurement in the recent record—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—targets a different active pharmaceutical ingredient and does not reflect the code's stated product line. A Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs represents exploratory market intelligence rather than procurement of a specific pharmaceutical product. State and local governments buying under this code, when activity occurs, source pharmaceutical preparations through health departments, county health systems, and state HHS agencies, typically embedded in broader pharmaceutical supply or managed care contracts.

Geographic activity is sparse and geographically dispersed. The recent Seminole County, Florida IFB represents the clearest state-local engagement, with a response deadline of July 26, 2023 (note: the posting date of June 30, 2026 appears inconsistent with the 2023 response date in the source). The Texas RFI, posted April 3, 2026 with the same-day response deadline, reflects state-level interest in pharmaceutical distribution models rather than procurement of methixene or metixene specifically. No issuing bodies appear as repeat buyers under this code in the available record, and no geographic concentration emerges. The code shows insufficient recent activity to characterize market demand or support a pursue decision at this time.